Company intelligence / Profile preview

eFFECTOR Therapeutics

San Diego or formerly Solana Beach, California, United Stateseffector.com ↗

Ownership: Public · EFTR
Employees: ~14
Development stage: Phase 2

Overview

The company’s lead candidate tomivosertib, an MNK inhibitor, was evaluated in a randomized Phase 2b trial in combination with pembrolizumab for metastatic NSCLC. Zotatifin, an eIF4A inhibitor, was in a Phase 1/2 trial for certain solid tumors. A third program targeted eIF4E inhibitors. The company ceased operations as of early/mid–2025 and clinical results are not being further advanced.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

tomivosertib

1 more asset in the full pipeline.

Request access →

Partnerships

Collaborated with Merck for KEYTRUDA combination studiesacademic collaborations not specified but referenced investigator-sponsored trials and research center partnerships.

Financials

Market cap: $3.8K
Total revenue: $0
Enterprise value: $-5.1M

Beyond the preview

Go deeper on eFFECTOR Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eFFECTOR Therapeutics.

Explore the full profile